(Q35880224)

English

Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer

scientific article published on 28 December 2015

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

0 references

Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Carlo La Vecchia

6

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

object named as

Lorenzo Moja

8

0 references

7

object named as

Eva Negri

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Corrado Blandizzi

object named as

Corrado Blandizzi

5

0 references

Martina Bonifazi

3

object named as

Martina Bonifazi

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

author name string

Stefania Mantarro

1

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Marta Rossi

2

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Roberto D'Amico

4

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

publication date

28 December 2015

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Internal and emergency medicine

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

123-140

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Clinical cardiac tolerability of trastuzumab

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Trastuzumab-related cardiotoxicity in early breast cancer: a cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Transformations Related to the Angular and the Square Root

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Quantifying heterogeneity in a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patients

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Assessment of adjuvant trastuzumab-associated cardiac toxicity in korean patients with breast cancer: a single-center analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Trastuzumab-related cardiac events in the treatment of early breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 - a prospective study

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Lack of uniformity in cardiac assessment during trastuzumab therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Are there benefits in routine clinical practice of continuing trastuzumab after progression for metastatic breast cancer patients?

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines--a phase II multipractice study

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (H

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active th

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

The binomial distribution of meta-analysis was preferred to model within-study variability.

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study

1 reference

https://api.crossref.org/works/10.1007%2FS11739-015-1362-X

21 January 2018

The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26712595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab-containing regimens for metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26712595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab-Induced Cardiomyopathy: Not as Benign as it Looks? A Retrospective Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26712595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of overall survival between the early use and delayed use of Trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26712595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26712595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

https://pubmed.ncbi.nlm.nih.gov/26712595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab containing regimens for early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26712595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiac side effects of trastuzumab in breast cancer patients - single centere experiences

1 reference

https://pubmed.ncbi.nlm.nih.gov/26712595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/26712595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM

1 reference

https://pubmed.ncbi.nlm.nih.gov/26712595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/26712595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era

1 reference

https://pubmed.ncbi.nlm.nih.gov/26712595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed?

1 reference

https://pubmed.ncbi.nlm.nih.gov/26712595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Surrogate end points in heart failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/26712595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998-2005.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26712595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11739-015-1362-X

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35880224&oldid=2197906630"